It is now nearly 50 years since the description of staphylococcal toxic shock syndrome (TSS) in children by James Todd in 1978.1 Streptococcal TSS-like syndrome was first reported in 1987.2 TSS is now ...

The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...

For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole ...

Purpose Toxic shock syndrome (TSS) is a rare disease responsible for significant morbidity and mortality. Intravenous immunoglobulin (IG) therapy in paediatric TSS could improve shock and organ ...

AIC, a division of AIS Healthcare, now offers YIMMUGO®, manufactured by Kedrion Biopharma, for the treatment of primary humoral immunodeficiency in patients 2 years of age and older. Approved by the U ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Objective To evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumour activity of AMG 404, a fully human IgG1 monoclonal antibody targeting programmed cell death-1, in ...

Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial evaluating ...

Department of Hematology, Haikou Municipal Hospital and Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China Pregnancy can lead to the recurrence or ...

According to Nova One Advisor, the global Intravenous Immunoglobulin market size was estimated at USD 14.25 billion in 2024 and is expected to hit around USD 28.83 billion by 2034, poised to grow at a ...